This material is intended for reference by healthcare professionals only

Beyond Weight Loss: GLP-1 Rewrites the Treatment Approach to Sleep Apnea

Obstructive sleep apnea (OSA) affects nearly 1 billion people worldwide, and moderate-to-severe OSA is closely associated with hypertension, atrial fibrillation, stroke, insulin resistance, and an increased risk of all-cause mortality. For a long time, continuous positive airway pressure (CPAP) has been the primary treatment, but adherence has always been a clinical challenge—fewer than half of patients can persist in using it for more than 4 hours per night. Over the past two years, GLP-1 drugs represented by tirzepatide and semaglutide are opening a crack in this situation.

SURMOUNT-OSA: A Trial That Changed Clinical Expectations

The SURMOUNT-OSA phase III trial, published in the New England Journal of Medicine in March 2024, enrolled 469 patients with moderate-to-severe OSA and obesity, divided into two cohorts: cohort 1, who could not tolerate or were unwilling to use CPAP, and cohort 2, who were already using CPAP. Participants were randomized to receive once-weekly tirzepatide (maximum dose 15 mg) or placebo for 52 weeks. The results were particularly striking in cohort 1: the apnea-hypopnea index (AHI) decreased by an average of about 55%, compared with only about 10% in the placebo group; more than one-third of patients had their AHI reduced to the normal range (<5 events/hour); body weight decreased by an average of about 18%–20%, and the improvement in AHI remained significant after adjustment for weight change, suggesting that the drug may act through mechanisms beyond weight loss (such as reducing inflammation of the soft tissues surrounding the upper airway and improving respiratory center regulation); patient-reported daytime sleepiness, quality of life, and sleep satisfaction all improved significantly. In cohort 2, tirzepatide further reduced AHI and significantly improved body weight and metabolic indicators.

This Is Not a "Cure," but an Expansion of the Treatment Paradigm

Several points need to be viewed calmly: the risk of rebound after discontinuation is real. The weight rebound phenomenon of GLP-1 drugs has been repeatedly observed in trials such as STEP-4, and whether AHI will rebound as weight rises again still requires longer follow-up data. CPAP remains the foundational treatment for most patients with moderate-to-severe OSA, especially for those with comorbid cardiovascular disease. Drugs are more suitable as part of comprehensive weight and metabolic management, rather than simply replacing ventilation therapy. The trial population was predominantly obese (BMI ≥28), and the conclusions cannot be directly extrapolated to non-obese OSA patients (such as those caused by craniofacial structural abnormalities). The gastrointestinal adverse reactions, gallbladder events, pancreatitis risk, and long-term safety of GLP-1 drugs still require monitoring.

Clinical Implications: Metabolism and Sleep Are Converging

The significance of SURMOUNT-OSA goes beyond "yet another indication." Together with the 2023 SELECT trial (in which semaglutide reduced major cardiovascular events by 20% in non-diabetic obese populations), it outlines a clearer path: obesity is not simply a lifestyle problem, but a chronic metabolic disease requiring long-term pharmacological management; treatment targeting it can simultaneously improve respiratory, cardiovascular, and metabolic outcomes. For clinicians, this means that when facing obese patients with comorbid OSA, in addition to referring them for sleep monitoring and prescribing CPAP, they should perhaps also jointly assess with endocrinology/weight management specialists whether adding GLP-1 drugs is appropriate. For patients, this means that "losing weight to save sleep" now has the support of high-quality randomized controlled evidence. Drugs will not replace lifestyle interventions and device therapy, but they are becoming a genuinely powerful new option in the comprehensive management of sleep apnea.ReferencesMalhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.N Engl J Med. 2024;390(9):787-799. DOI: 10.1056/NEJMoa2312446Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).N Engl J Med. 2023;389(24):2221-2233. DOI: 10.1056/NEJMoa2307563Benjafield AV, Ayas NT, Eastwood PR, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.Lancet Respir Med. 2019;7(8):687-698. DOI: 10.1016/S2213-2600(19)30198-5Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP-4 extension).Diabetes Obes Metab. 2022;24(8):1573-1583. DOI: 10.1111/dom.14725

Disclaimer: This material is intended for academic exchange among healthcare professionals only and does not constitute promotion or prescribing advice for any drug. The use of drugs mentioned herein should strictly follow their latest prescribing information and the regulatory requirements of the relevant region. This material is not intended as promotional material for the general public.

© 2026 Sun Shenghua (Beijing) Medical Technology Co., Ltd.